文献速递头颈外科

帕博利珠单抗联合西妥昔单抗及新辅助化疗治疗头颈部鳞状细胞癌

Pembrolizumab plus cetuximab with neoadjuvant chemotherapy for head and neck squamous cell carcinoma.
PubMed 文献 · Head Neck · 2024-08-13

本研究回顾性分析2021年1月至2024年6月在仁济医院接受新辅助免疫化疗后行根治性手术及完整颈部淋巴结清扫的头颈部鳞状细胞癌患者21例,主要终点为主要病理缓解(MPR),结果为66.7%,其中11例达病理完全缓解(pCR),总缓解率(ORR)为90.5%,完全缓解(CR)率为28.6%,最常见不良事件为贫血(61.9%),未报告4级不良事件或手术延迟,结论认为帕博利珠单抗联合西妥昔单抗及化疗是可行且安全的临床方案。

要点

  • 21例头颈部鳞状细胞癌患者接受新辅助免疫化疗,MPR为66.7%,pCR 11例。
  • ORR为90.5%,CR率为28.6%,口咽原发部位为敏感肿瘤类型。
  • 最常见不良事件为贫血(61.9%),未报告4级不良事件或手术延迟。

核心结论

  • 帕博利珠单抗联合西妥昔单抗及化疗治疗头颈部鳞状细胞癌是可行且安全的临床方案,可实现器官保留和生活质量改善。
  • 治疗前外周免疫指标有助于筛选可能对新辅助免疫化疗应答的患者。

研究设计与样本

  • 回顾性分析2021年1月至2024年6月在仁济医院接受新辅助免疫化疗后行根治性手术及完整颈部淋巴结清扫的头颈部鳞状细胞癌患者21例。
  • 主要终点为主要病理缓解(MPR),并进一步探索疗效与免疫指标的关系。

主要发现

  • MPR为66.7%,其中11例患者达到病理完全缓解(pCR)。
  • 总缓解率(ORR)为90.5%,完全缓解(CR)率为28.6%。
  • 口咽作为原发部位是对新辅助免疫化疗敏感的肿瘤类型。
  • 最常见不良事件为贫血(61.9%),未报告4级不良事件或手术延迟。
  • 喉保留率为90.9%(10/11),所有患者病理学检查证实手术切缘阴性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Head and neck cancer cells commonly express programmed death ligand 1 (PD-L1) and epidermal growth factor receptor (EGFR), both of which play pivotal roles in the antitumor cellular immune response. Pembrolizumab, a PD-1 inhibitor, and cetuximab, an EGFR inhibitor, are typically effective agents combined with neoadjuvant platinum-based chemotherapy for the treatment of head and neck squamous cell carcinoma (HNSCC). This study aims to evaluate the efficacy and safety of neoadjuvant immunochemotherapy in patients with HNSCC. METHODS: Patients with HNSCC underwent radical surgery and complete cervical lymph node dissection following neoadjuvant immunochemotherapy at RenJi Hospital from January 2021 to June 2024 were retrospectively analyzed. The primary endpoint was major pathological response (MPR). We further explored the relationship between the efficacy and immune estimators. FINDINGS: Twenty-one patients were enrolled in this retrospective study. The MPR was 66.7%, including 11 patients who achieved a pathological complete response (pCR). The overall response rate (ORR) was 90.5%, and the complete response (CR) rate was 28.6%. The oropharynx, as the primary site, was the sensitive tumor type to neoadjuvant immunochemotherapy. The most common adverse event (AEs) was anemia (61.9%). No grade 4 AE or delayed surgery was reported. Laryngeal preservation rates were 90.9% (10/11), and pathological findings confirmed negative surgical margins for all patients. Moreover, pre-treatment peripheral lymphocyte count, monocyte count, and platelet to lymphocyte ratio (PLR) displayed a significant correlation with the treatment response. CONCLUSION: Pembrolizumab plus cetuximab with chemotherapy for patients with HNSCC is a feasible and safe clinical protocol fulfilling organ preservation and life quality improvement. Pre-treatment peripheral immune estimators could help to screen patients who may respond to the neoadjuvant immunochemotherapy.

来源:Head Neck,查看原文。版权归原作者所有。

引用

  1. Yao Z, Wang J, Jiang Y, et al. Pembrolizumab plus cetuximab with neoadjuvant chemotherapy for head and neck squamous cell carcinoma. Head Neck. 2024. PMID: 39138647. doi:10.1002/hed.27915

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。